Prognostic factors in clear cell carcinoma of endometrium: analysis of 55 cases

Background and aim of the work: The purpose of this study was to evaluate the clinical and pathologic prognostic factors associated with survival in patients with clear cell carcinoma (CCC) of the endometrium. Methods: A retrospective review of fifty-five patients with endometrial clear cell carcinoma were collected. Results: The median overall and disease-free survivals were 40 and 20 months, respectively. A univariate analysis was performed with respect to stage of disease, age, lymph nodes status, myometrium invasion, lymph vascular space invasion and adjuvant therapy. Stage was found to be the only important prognostic factor related to survival. In fact, early stage had a median survival of 77 months compared to 34 months in the advanced disease (p<0.04). These differences remained significant after adjusting for single stage (stage III versus IV). Conclusions: Endometrial CCC is a rare histotype. Advanced stage disease is considered a poor prognostic factor. Recurrences are high even in early stage. Randomized clinical trials are needed. (www.actabiomedica.it)

[1]  D. La Forgia,et al.  A Machine Learning Tool to Predict the Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer , 2021, Applied Sciences.

[2]  F. Arezzo,et al.  Complete Hydatidiform Mole Mimicking Sacroiliitis. , 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[3]  D. Mutch,et al.  Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases , 2017, International Journal of Gynecologic Cancer.

[4]  Ahmedin Jemal,et al.  Global Cancer in Women: Burden and Trends , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[5]  M. Arvas,et al.  Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study , 2017, Journal of gynecologic oncology.

[6]  I. Selcuk,et al.  Prognostic factors in endometrial clear cell carcinoma , 2016, Archives of Gynecology and Obstetrics.

[7]  H. Mahdi,et al.  Prognostic impact of lymphadenectomy in uterine clear cell carcinoma , 2015, Journal of gynecologic oncology.

[8]  J. Debus,et al.  Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy , 2014, Radiation oncology.

[9]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[10]  J. Hecht,et al.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. , 2013, American journal of cancer research.

[11]  R. Yechieli,et al.  The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma. , 2012, Gynecologic oncology.

[12]  Herbert Yu,et al.  Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression , 2011, Journal of oncology.

[13]  S. Lax [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology]. , 2011, Der Pathologe.

[14]  A. Gadducci,et al.  Clear cell carcinoma of the endometrium: a biological and clinical enigma. , 2010, Anticancer research.

[15]  F. Amant,et al.  The Use of Lymph Vessel Markers to Predict Endometrial Cancer Outcome , 2010, International Journal of Gynecologic Cancer.

[16]  A. Olawaiye,et al.  Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[17]  D. Mutch,et al.  Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. , 2008, Gynecologic oncology.

[18]  M. Carey,et al.  Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? , 2007, International Journal of Gynecologic Cancer.

[19]  O. Fadare,et al.  Precursors of Endometrial Clear Cell Carcinoma , 2006, The American journal of surgical pathology.

[20]  R. Barakat,et al.  Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. , 2006, Gynecologic oncology.

[21]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[22]  A. Mundt,et al.  Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. , 2003, International journal of radiation oncology, biology, physics.

[23]  V. Abeler,et al.  Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern , 1996, Cancer.

[24]  J. V. Bokhman Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[25]  D. Edelman,et al.  Clear cell carcinoma of the endometrium , 1979, Cancer.